Dear Colleagues,

Breast cancer is one of the most common oncological diseases affecting women. Hormone therapy is a commonly used strategy to treat breast cancer due to the estrogen-dependent nature of many breast cancer subtypes. In the most aggressive subtype, triple-negative breast cancer, treatment with hormone therapy or with HER2 inhibitors is ineffective. A better understanding of the biological heterogeneity of breast cancer is therefore needed in order to discover new therapeutic targets and to develop more effective and individualized treatments. Special attention must also be paid to the emergence of drug resistance, which is a major challenge to the successful development of targeted therapy for different molecular subtypes of breast cancer. This includes the use of more advanced methods to identify changes induced by drug treatment that may be related to compensatory signaling pathways in drug-resistant cancer cells.

This Special Issue will focus on current approaches and emerging novel strategies for local and systemic therapy of the major molecular subtypes of breast cancer. Clinical, molecular and biochemical studies that aim to expand our understanding of this tumor and its successful treatment are welcome.

Prof.  Rumiana Tzoneva

Guest Editor